Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 3Myeloid 2Lymphoid 1Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CA-4948 × Genitourinary × 1 year × Clear all
NCT06439836 2026-05-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

National Cancer Institute (NCI)

Phase 1 Recruiting
27 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡